These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27024316)

  • 1. Ask the doctor. Do vaginal estrogens that are used for vaginal dryness have the same risks as estrogen taken orally or by skin patch?
    Robb-Nicholson C
    Harv Womens Health Watch; 2011 Dec; 19(4):8. PubMed ID: 27024316
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing postmenopausal vaginal atrophy. Vaginal dryness is one of the most irritating symptoms of menopause. Here are some ways to relieve it.
    Harv Womens Health Watch; 2010 Mar; 17(7):4-5. PubMed ID: 20480969
    [No Abstract]   [Full Text] [Related]  

  • 3. By the way, doctor. After stopping Prempro last year, I developed really uncomfortable vaginal dryness. My doctor has recommended the vaginal estrogen ring. Is it safe?
    Robb-Nicholson C
    Harv Womens Health Watch; 2003 Feb; 10(6):8. PubMed ID: 12604440
    [No Abstract]   [Full Text] [Related]  

  • 4. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I stopped taking oral estrogen pills, and now vaginal dryness is a problem. My doctor suggested I use a vaginal cream containing estrogen. Is estrogen given this way absorbed by the body?
    Mayo Clin Health Lett; 2003 Aug; 21(8):8. PubMed ID: 12971311
    [No Abstract]   [Full Text] [Related]  

  • 6. [Local estrogen therapy--clinical implications--2012 update].
    Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
    Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies for postmenopausal vaginal atrophy.
    Pickar JH
    Maturitas; 2013 May; 75(1):3-6. PubMed ID: 23434231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy.
    Rees M; Pérez-López FR; Ceasu I; Depypere H; Erel T; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; van der Schouw Y; Tremollieres F;
    Maturitas; 2012 Oct; 73(2):171-4. PubMed ID: 22818886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in vaginal dryness according to hormone therapy schedule using pH test strip in two groups of postmenopausal women.
    Carranza-Lira S; MacGregor-Gooch AL
    Int J Fertil Womens Med; 2004; 49(2):88-90. PubMed ID: 15188835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy.
    Nappi RE; Murina F; Perrone G; Villa P; Biglia N
    Minerva Ginecol; 2017 Aug; 69(4):370-380. PubMed ID: 28398023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women.
    Goldstein I; Alexander JL
    J Sex Med; 2005 Sep; 2 Suppl 3():154-65. PubMed ID: 16422792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women.
    Suwanvesh N; Manonai J; Sophonsritsuk A; Cherdshewasart W
    Menopause; 2017 Feb; 24(2):210-215. PubMed ID: 27749740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in maturation index and vaginal dryness after treatment with topical conjugated estrogens in low and conventional dose].
    Carranza-Lira S; de Jesús Cabrera-López T; Estrada-Moscoso I; Aguado-Pérez RA
    Rev Med Inst Mex Seguro Soc; 2012; 50(3):315-8. PubMed ID: 23182262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of local estrogen therapy for urogenital atrophy.
    Archer DF
    Menopause; 2010; 17(1):194-203. PubMed ID: 19602990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients.
    Del Pup L
    Gynecol Endocrinol; 2012 Sep; 28(9):740-5. PubMed ID: 22409649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.